Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05758324
Other study ID # 2022-A01340-43
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date January 31, 2024

Study information

Verified date March 2023
Source Laboratoires Pronutri
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obstructive sleep apnea syndrome (OSA) is defined by the association of clinical symptoms - drowsiness in particular - and sleep breathing disorders, objectified by measuring the apnea-hypopnea index (AHI). Apneas and hypopneas during sleep are responsible for micro-arousals and hypoxemia. In the short term, these result in daytime sleepiness with reduced alertness, difficulty driving and carrying out tasks (increased risk of road accidents and accidents at work), memory and concentration problems. , mood disorders. These disturbances lead to an impairment of the quality of life. In the long term, severe OSA (AHI > 30 events/hour) increases all-cause mortality and cardiovascular morbidity. The reference treatment is nasal ventilation by Continuous Positive Airway Pressure (CPAP). In practice, the observance and effectiveness of CPAP are limited by the sometimes difficult acceptance of cumbersome equipment, involving noise pollution and requiring the wearing of night-time equipment that some patients find difficult to bear. The alternative treatment is represented by the mandibular advancement orthosis . Lifestyle and dietary measures are always recommended. To date, no pharmacological treatment has demonstrated its effectiveness in OSA. Studies have shown that the antioxidant capacity of the blood is reduced in patients with OSA. It would be secondary to the cycles of hypoxia and reoxygenation which cause a modification of the oxidative balance, leading to an increase in free radicals. It has been observed that the serum levels of trace elements and heavy metals are higher during OSA, by deterioration of the balance of these substances due to oxidative stress and inflammation. Antioxidant therapies have reduced biomarkers of oxidative stress in apneic patients. A new path of research is opening up with the use of antioxidants and trace elements in OSA. To scientifically support the hypothesis of the action of these supplements based on trace metals on OSA, PRONUTRI wish to conduct a comparative, randomized, double-blind study versus placebo evaluating the effect of a specific complex of trace metals in the OSA.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 42
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adult patient with moderate to severe sleep apnea-hypopnea syndrome confirmed by polysomnography dating less than 3 months with an apneas/hypopneas index = 15 events/h - stable weight (5% variation of the weight at the time of the polysomnography done within 3 months) Exclusion Criteria: - patient previously treated for OSA by continuous positive airway pressure or mandibular orthosis - obesity (body mass index > 30 kg/m2) - pregnant or post-pregnancy women less than 6 months old or of childbearing age without an effective method of contraception - respiratory, cardiac, hepatic or renal failure - active cancer or history of cancer - alcohol abuse - antidepressant intake - use of compression stockings - intake of product or supplementation enriched with trace metals and/or trace elements and/or mineral salts and/or vitamins. - taking any type of psychotropic medication - previous intake of trace elements to treat OSA

Study Design


Intervention

Dietary Supplement:
Nutri PNEA
4 sequences of 10 tablets (one intake)
Placebo
4 sequences of 10 tablets (one intake)

Locations

Country Name City State
France Laboratoire EFCR - CHU de Grenoble Grenoble

Sponsors (2)

Lead Sponsor Collaborator
Laboratoires Pronutri Clin-Experts

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the number of apneas/hypopneas 60 days
Secondary Change in Ventilatory Response Change in Ventilatory Response assessed by tests of Ventilatory Response to Carbon Dioxide (CO2) 60 days
Secondary Proportion of patients with a 50% reduction in the apnea-hypopnea index AHI is used to diagnose obstructive sleep apnea by counting respiratory events. An index greater than 5 per hour defines a ventilatory disorder.
AHI defines severity as well, the index is:
Mild, between 5 and 15 per hour Moderate, between 15 and 30 per hour Severe, over than 30 per hour
60 days
Secondary Proportion of patients with an apnea-hypopnea index < 30/hour AHI is used to diagnose obstructive sleep apnea by counting respiratory events. An index greater than 5 per hour defines a ventilatory disorder.
AHI defines severity as well, the index is:
Mild, between 5 and 15 per hour Moderate, between 15 and 30 per hour Severe, over than 30 per hour
60 days
Secondary Proportion of patients with an apnea-hypopnea index < 15/hour AHI is used to diagnose obstructive sleep apnea by counting respiratory events. An index greater than 5 per hour defines a ventilatory disorder.
AHI defines severity as well, the index is:
Mild, between 5 and 15 per hour Moderate, between 15 and 30 per hour Severe, over than 30 per hour
60 days
Secondary Change in sleep quality Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI) questionnaire. This will be used to measure sleep quality over the last 60 days.The self-related questions include the assessment of seven different sleep domains : sleep quality, sleep latency , sleep duration , habitual sleep efficiency, sleep disturbances , use of sleeping medications , and daytime dysfunction .The seven components scores are then added to yield a global PSQI score in the range of zero to 21. The higher the score, the worse the sleep quality. A global score greater than five is diagnostic of poor sleep quality. 60 days
Secondary Change in sleepiness Sleepiness will be assessed by the Epworth Sleepiness Scale (ESS).It will be used to measure daytime sleepiness .It can determine the chance of falling asleep in 8 different circumstances. ESS score can range from 0 to 24. A global score greater than ten is diagnostic of excessive daytime sleepiness . 60 days
See also
  Status Clinical Trial Phase
Completed NCT04925739 - Evaluation of the Comfort of a Continuous Positive Airway Pressure Nasal Mask in the Treatment of OSA Syndrome
Recruiting NCT04179188 - Impact of Bariatric Surgery in Obese Patients With and Without Obstructive Sleep Apnea Syndrome
Not yet recruiting NCT04131660 - Efficacy of Volume Ventilation in Patients With Acute Respiratory Failure at Risk of Obstructive Apneas or Obesity Hypoventilation N/A
Recruiting NCT04297163 - Telemonitoring for the Recuperation of Patients With CPAP N/A
Recruiting NCT05661747 - Dental Appliance to Treat SDB in Children Phase 4
Completed NCT03138850 - Improve Oxygenation and Capnographic Detection During Sedative EGD N/A
Not yet recruiting NCT06397365 - Effect of Hypnosis on Adherence to Continuous Positive Airway Pressure. N/A
Completed NCT03196583 - Efficacy of a Novel MAD in OSA N/A
Recruiting NCT06462287 - EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION Phase 2
Recruiting NCT05001464 - Evaluation of Reliability and Validity of Reflectance Pulse Oximeter in Screening Children With Obstructive Sleep Apnea
Active, not recruiting NCT04950894 - Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation N/A
Completed NCT03398044 - Administration of Dexamethasone in PONV Prophylaxis in Children Undergoing Adenotomy N/A
Active, not recruiting NCT04882020 - Inflammation and Neurocognitive Damage Markers in Elderly People With Obstructive Sleep Apnea
Completed NCT05532228 - Evaluation of the Functional Impact of Adenotonsilectomy
Not yet recruiting NCT03890549 - Validation of Downloadable Mobile Snore Applications by Polysomnography (PSG)